Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
434 studies found for:    "Cutaneous T-cell lymphoma"
Show Display Options
Rank Status Study
1 Terminated
Has Results
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
Conditions: Cutaneous T-cell Lymphoma Stage I;   Cutaneous T-cell Lymphoma Stage II;   Cutaneous T-cell Lymphoma Stage III;   Cutaneous T-cell Lymphoma Stage IV
Interventions: Drug: vorinostat;   Other: flow cytometry;   Other: laboratory biomarker analysis
2 Completed Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Pralatrexate Injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
3 Withdrawn Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Curcumin (Turmeric);   Behavioral: Questionnaires;   Other: Photos
4 Not yet recruiting Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
Conditions: Cutaneous T-cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Doxycycline monohydrate
5 Active, not recruiting Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
Conditions: Cutaneous T Cell Lymphoma;   Graft Versus Host Disease
6 Terminated Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
Conditions: Mycosis Fungoides;   Cutaneous T-Cell Lymphoma;   Neoplasms
Intervention: Drug: Romidepsin (FR901228)
7 Completed Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
Condition: Refractory Cutaneous T-cell Lymphoma
Intervention: Drug: bexarotene
8 Completed Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: Panobinostat
9 Completed A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Intervention: Drug: APO866
10 Completed LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Conditions: Tumors;   Cutaneous T-Cell Lymphoma
Intervention: Drug: LBH589
11 Recruiting Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T Cell Lymphoma
Intervention: Drug: Micro needle array-Doxorubicin (MNA-D)
12 Recruiting Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma;   Cutaneous T-cell Lymphoma
Intervention: Drug: E7777
13 Completed Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Intervention: Drug: LBH589
14 Withdrawn Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T-cell Lymphoma (CTCL)
Intervention: Drug: Sirolimus 0.1% Ointment
15 Unknown  Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Condition: Cutaneous T Cell Lymphoma
Intervention: Drug: Lenalidomide
16 Active, not recruiting Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma (CTCL)
Intervention: Drug: SHAPE
17 Terminated Efficacy & Safety Study of Selinexor in Relapsed/Refractory Peripheral T-cell Lymphoma & Cutaneous T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (PTCL);   Cutaneous T-cell Lymphoma (CTCL)
Intervention: Drug: Selinexor
18 Recruiting Safety, Tolerability and Pharmacokinetic Study of MRG-106 in Patients With Cutaneous T Cell Lymphoma (CTCL), MF Subtype
Conditions: Cutaneous T-cell Lymphoma (CTCL);   Mycosis Fungoides
Intervention: Drug: MRG-106
19 Recruiting A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Condition: Persistent or Recurrent Cutaneous T-Cell Lymphoma
Intervention: Drug: E7777
20 Recruiting Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions: Drug: carfilzomib;   Drug: romidepsin;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years